These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24987866)

  • 1. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.
    Sirtori CR; Pavanello C; Bertolini S
    Ann Med; 2014 Nov; 46(7):464-74. PubMed ID: 24987866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
    Vuorio A; Tikkanen MJ; Kovanen PT
    Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomitapide for the treatment of hypercholesterolemia.
    Berberich AJ; Hegele RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1261-1268. PubMed ID: 28598687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsomal transfer protein inhibition in humans.
    Cuchel M; Rader DJ
    Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.
    Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA
    Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia.
    Rizzo M
    IDrugs; 2010 Feb; 13(2):103-11. PubMed ID: 20127562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide.
    Giammanco A; Cefalù AB; Noto D; Averna MR
    Curr Med Chem; 2020; 27(23):3773-3783. PubMed ID: 30663562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
    Davis KA; Miyares MA
    Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lomitapide for the management of homozygous familial hypercholesterolemia.
    deGoma EM
    Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
    Perry CM
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Lomitapide in Hypercholesterolemia.
    Liu X; Men P; Wang Y; Zhai S; Zhao Z; Liu G
    Am J Cardiovasc Drugs; 2017 Aug; 17(4):299-309. PubMed ID: 28255870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.
    Raal FJ; Santos RD
    Atherosclerosis; 2012 Aug; 223(2):262-8. PubMed ID: 22398274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Homozygous hypercholesterolemia - new therapeutic options in cases with complete lack of LDL- receptor].
    Mellwig KP; Farr M; Diekmann J; Horstkotte D; van Buuren F
    Dtsch Med Wochenschr; 2016 Jun; 141(12):878-81. PubMed ID: 27305304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia.
    Walsh MT; Hussain MM
    Crit Rev Clin Lab Sci; 2017 Jan; 54(1):26-48. PubMed ID: 27690713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
    Ito MK; Watts GF
    Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.